Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.51 |
| ▸ | PLAU | P00749 | 1/20 | 0.51 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.51 |
| ▸ | ELANE | P08246 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 7/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 10/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.45 |
| ▸ | MEN1 | O00255 | 6/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | GAA | P10253 | 4/20 | 0.44 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21883217 | 0.84 | FBP1 (0.47) | F2PLAUKLKB1ELANELMNA | |
| SCHEMBL21883137 | 0.83 | SMN1; SMN2 (0.49) | LMNASMN1; SMN2MAPTKMT2AMEN1 | |
| SCHEMBL21883121 | 0.82 | KMT2A (0.51) | LMNASMN1; SMN2IDO1MAPTKMT2A | |
| SCHEMBL18604415 | 0.78 | ALDH1A1 (0.46) | LMNASMN1; SMN2MAPTKMT2AMEN1 | |
| SCHEMBL21883140 | 0.77 | NPC1 (0.47) | LMNASMN1; SMN2MAPTKMT2AMEN1 | |
| SCHEMBL21883221 | 0.77 | MAPT (0.46) | F2PLAUKLKB1ELANELMNA | |
| SCHEMBL21883142 | 0.77 | SMN1; SMN2 (0.49) | ELANELMNASMN1; SMN2IDO1MAPT | |
| SCHEMBL21883243 | 0.77 | TDP1 (0.47) | LMNASMN1; SMN2IDO1MAPTKMT2A | |
| SCHEMBL21883273 | 0.76 | LMNA (0.51) | LMNASMN1; SMN2MAPTKMT2AMEN1 | |
| SCHEMBL21883224 | 0.75 | RAB9A (0.54) | LMNASMN1; SMN2MAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12534440-B2 | Compounds with copper- or zinc-activated toxicity against microbial infection | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2026-01-27 | — | — | US | disclosed |
| US-20220024877-A1 | COMPOUNDS WITH COPPER- OR ZINC-ACTIVATED TOXICITY AGAINST MICROBIAL INFECTION | THE UAB RESEARCH FOUNDATION | 2022-01-27 | — | — | US | disclosed |
| US-20220024877-A1 | COMPOUNDS WITH COPPER- OR ZINC-ACTIVATED TOXICITY AGAINST MICROBIAL INFECTION | THE UAB RESEARCH FOUNDATION | 2022-01-27 | — | — | US | disclosed |
| WO-2020061412-A1 | COMPOUNDS WITH COPPER- OR ZINC-ACTIVATED TOXICITY AGAINST MICROBIAL INFECTION | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12534440-B2 | Compounds with copper- or zinc-activated toxicity against microbial infection | TST, SLC39A11, SLC39A3 | F2 3320/4885PLAU 4376/4885KLKB1 4691/4885 |
| US-20220024877-A1 | COMPOUNDS WITH COPPER- OR ZINC-ACTIVATED TOXICITY AGAINST MICROBIAL INFECTION | SLC39A11, CNBP, SLC39A3 | F2 4161/4885PLAU 4121/4885KLKB1 3576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.